Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Glide paths in target date funds describe how asset allocations shift automatically as retirement nears, balancing growth and risk over time. This intro explains the idea and why it matters for planning.
25,488 articlesLilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
A sudden price collapse in a toll-tech stock creates a rare chance for patient investors. This guide explains how to ...
When SpaceX surged, several smaller space stocks fell hard. Was it just rotation, or a signal to rethink the sector? ...
A wave of institutional money into DeFi may ride through the front ends users touch every day, not via on-chain walle...
Iraq signals a possible exit from OPEC, fueling bets that a world rejecting opec controls could unleash softer oil pr...
SpaceX blends rockets, satellites, and AI dreams. This piece examines whether could spacex eventually become the top ...
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A Goldman Sachs economist offers reality on AI adoption timing, arguing that productivity gains from AI are likely to...
Qualcomm's AI data-center push is fueling a fresh round of upside bets, with investors watching for a sustained ramp ...
A veteran journalist outlines Elliott Investment Management’s influence on Norwegian Cruise Line amid a strong cruise...
A sharp drop in Oddity Tech shares sparked questions about the health of a high-growth tech play. Even with solid qua...
Vitalik Buterin unveiled a bold two-part plan to overhaul Ethereum's execution layer, aiming to boost scalability and...